Bausch Health Net Interest Income Over Time
| BHC Stock | USD 5.97 0.13 2.23% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bausch Health Performance and Bausch Health Correlation. Will Pharmaceuticals sector continue expanding? Could Bausch diversify its offerings? Factors like these will boost the valuation of Bausch Health. Projected growth potential of Bausch fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bausch Health data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 13.68 | Earnings Share 0.97 | Revenue Per Share | Quarterly Revenue Growth 0.068 | Return On Assets |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bausch Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bausch Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bausch Health's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Interest Income Analysis
Compare Bausch Health Companies and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Interest Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COR | (157.8 M) | (157.8 M) | (157.8 M) | (157.8 M) | (157.8 M) | (157.8 M) | (157.8 M) | (157.8 M) | (157.8 M) | (137.9 M) | (174.1 M) | (210.7 M) | (228.9 M) | (157 M) | (291.5 M) | (262.4 M) | (275.5 M) |
| REGN | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (25.1 M) | (28.2 M) | (30.2 M) | (56.9 M) | (57.3 M) | 100.7 M | 345.6 M | 656.2 M | 673 M | 706.6 M |
| IDXX | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (32 M) | (33.6 M) | (30.6 M) | (32.5 M) | (29.4 M) | (38.8 M) | (43.6 M) | (18.5 M) | (16.7 M) | (17.5 M) |
| HLN | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (9 M) | (2 M) | (207 M) | (368 M) | (339 M) | (305.1 M) | (289.8 M) |
| CI | (252 M) | (252 M) | (252 M) | (252 M) | (252 M) | (252 M) | (252 M) | (252 M) | (498 M) | (1.7 B) | (1.4 B) | (1.2 B) | (1.2 B) | (1.4 B) | (1.4 B) | (1.3 B) | (1.4 B) |
| ELV | (723 M) | (723 M) | (723 M) | (723 M) | (723 M) | (723 M) | (723 M) | (739 M) | (753 M) | (746 M) | (784 M) | (798 M) | (851 M) | (1000 M) | (1.2 B) | (1.4 B) | (1.5 B) |
| BDX | (367 M) | (367 M) | (367 M) | (367 M) | (367 M) | (367 M) | (445 M) | (641 M) | (627 M) | (521 M) | (460 M) | (382 M) | (403 M) | (365 M) | (575 M) | (661.2 M) | (694.3 M) |
| ARGX | 61 K | 61 K | 61 K | 61 K | 61 K | 61 K | 61 K | 165 K | 1.4 M | 7.8 M | (1.4 M) | (944 K) | 23.8 M | 92.1 M | 136.3 M | 156.7 M | 164.6 M |
| TAK | (11 B) | (11 B) | (11 B) | (11 B) | (11 B) | (11 B) | (11 B) | 7.6 B | (61 B) | (146.6 B) | (143.1 B) | (142.9 B) | (106.8 B) | (140.5 B) | (160.6 B) | (144.5 B) | (151.7 B) |
Bausch Health Companies and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Interest Income description
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.My Equities
My Current Equities and Potential Positions
| Bausch Health Companies | BHC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2150 St ElzEar |
| Exchange | New York Stock Exchange |
USD 5.97
Check out Bausch Health Performance and Bausch Health Correlation. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Bausch Health technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.